Treatment of bacterial infections in obese adult patients: how to appropriately manage antimicrobial dosage

Current Opinion in Pharmacology

Volumn 24, Issue , 2015, Pages 12-17

  Pai, Manjunath P ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM; CEFAZOLIN; COLISTIN; DAPTOMYCIN; FOSFOMYCIN; GLYCOPEPTIDE; GLYCYCLINE DERIVATIVE; KETOLIDE; LEVOFLOXACIN; LINCOSAMIDE; LIPOGLYCOPEPTIDE; LIPOPEPTIDE; MACROLIDE; MEROPENEM; NITROIMIDAZOLE; OXAZOLIDINONE DERIVATIVE; POLYMYXIN B; QUINOLONE DERIVATIVE; STREPTOGRAMIN DERIVATIVE; SULFONAMIDE; TELAVANCIN; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTICLE; BACTERIAL INFECTION; BODY SIZE; BODY WEIGHT; DRUG DOSE REGIMEN; DRUG MONITORING; HUMAN; KIDNEY FUNCTION; MAINTENANCE DRUG DOSE; NEPHROTOXICITY; OBESITY; PRIORITY JOURNAL; ADULT; BACTERIAL INFECTIONS; DOSE RESPONSE;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OBESITY;

EID: 84934945618     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.06.004     Document Type: Review

References (50)

1. M. Ng, T. Fleming, M. Robinson, B. Thomson, N. Graetz, C. Margono, E.C. Mullany, S. Biryukov, and C. Abbafati Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 384 2014 766 781
2. BMI Classification. World Health Organization. Global Database on body mass index. http://apps.who.int/bmi/index.jsp?introPage=intro-3.html (accessed 25.04.15).
3. C.A. Roberto, B. Swinburn, C. Hawkes, T.T. Huang, S.A. Costa, M. Ashe, L. Zwicker, J.H. Cawley, and K.D. Brownell Patchy progress on obesity prevention: emerging examples, entrenched barriers, and new thinking Lancet 2015 pii:S0140-6736(14)61744-X
4. C.L. Ogden, C.D. Fryar, M.D. Carroll, and K.M. Flegal Mean body weight, height, and body mass index, United States 1960-2002 Adv Data 347 2004 1 17
5. P.Y. Han, S.B. Duffull, C.M. Kirkpatrick, and B. Green Dosing in obesity: a simple solution to a big problem Clin Pharmacol Ther 82 2007 505 508
6. R.H. Mathijssen, and A. Sparreboom Influence of lean body weight on anticancer drug clearance Clin Pharmacol Ther 85 2009 23 author reply 24
7. M.P. Pai, and D.T. Bearden Antimicrobial dosing considerations in obese adult patients Pharmacotherapy 27 2007 1081 1091
8. M.J. Hanley, D.R. Abernethy, and D.J. Greenblatt Effect of obesity on the pharmacokinetics of drugs in humans Clin Pharmacokinet 49 2010 71 87
9. K.D. Payne, and R.G. Hall II Dosing of antibacterial agents in obese adults: does one size fit all? Expert Rev Anti Infect Ther 12 2014 829 854
10. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 10
11. P.L. Toutain, A. Bousquet-Mélou, and M. Martinez AUC/MIC: a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor? J Antimicrob Chemother 60 2007 1185 1188
12. M.N. Martinez, M.G. Papich, and G.L. Drusano Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target Antimicrob Agents Chemother 56 2012 2795 2805
13. F. Ehmann, M. Papaluca, F. Di Giuseppe, L. Pani, A. Eskova, E. Manolis, and R. Herold Changes and determination of dosing recommendations for medicinal products recently authorized in the European Union Expert Opin Pharmacother 16 2015 903 911
14. P.L. Toutain, and A. Bousquet-Mélou Volumes of distribution J Vet Pharmacol Ther 27 2004 441 453
15. S.C. McLeay, G.A. Morrish, C.M. Kirkpatrick, and B. Green The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007 Clin Pharmacokinet 51 2012 319 330
16. D.W. Bratzler, E.P. Dellinger, K.M. Olsen, T.M. Perl, P.G. Auwaerter, M.K. Bolon, D.N. Fish, L.M. Napolitano, R.G. Sawyer, and D. Slain American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America, Clinical practice guidelines for antimicrobial prophylaxis in surgery Am J Health Syst Pharm 70 2013 195 283
17. L.A. Marcos, B.C. Camins, D.J. Ritchie, E. Casabar, and D.K. Warren Acute renal insufficiency during telavancin therapy in clinical practice J Antimicrob Chemother 67 2012 723 726
18. M.P. Pai Comment on: Acute renal insufficiency during telavancin therapy in clinical practice J Antimicrob Chemother 67 2012 1300 1301
19. M.P. Pai Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults Pharmacotherapy 32 2012 856 868
20. Drugs@FDA Database. US Food and Drug Administration. 2014. Vancomycin Hydrochloride Label. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (accessed 25.04.15).
21. M.J. Rybak, B.M. Lomaestro, J.C. Rotschafer, R. Moellering, W. Craig, M. Billeter, J.R. Dalovisio, and D.P. Levine Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 2009 82 98
22. B. Green, and S.B. Duffull What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58 2004 119 133
23. M.P. Pai, and F.P. Paloucek The origin of the "ideal" body weight equations Ann Pharmacother 34 2000 1066 1069
24. L.A. Bauer, W.A. Edwards, E.P. Dellinger, and D.A. Simonowitz Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients Eur J Clin Pharmacol 24 1983 643 647
25. S. Janmahasatian, S.B. Duffull, S. Ash, L.C. Ward, N.M. Byrne, and B. Green Quantification of lean bodyweight Clin Pharmacokinet 44 2005 1051 1065
26. R.D. Mosteller Simplified calculation of body-surface area N Engl J Med 317 1987 1098
27. A.M. Sandri, C.B. Landersdorfer, J. Jacob, M.M. Boniatti, M.G. Dalarosa, D.R. Falci, T.F. Behle, R.C. Bordinhão, J. Wang, and A. Forrest Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens Clin Infect Dis 57 2013 524 531
28. M.P. Pai Polymyxin B dosing in obese and underweight adults Clin Infect Dis 57 2013 1785
29. C.B. Landersdorfer, R.L. Nation, A. Forrest, A.M. Sandri, A.P. Zavascki, and J. Li Reply to Pai Clin Infect Dis 57 2013 1786
30. Y. Dubrovskaya, N. Prasad, Y. Lee, D. Esaian, D.A. Figueroa, and V.H. Tam Risk factors for nephrotoxicity onset associated with polymyxin B therapy J Antimicrob Chemother 2015 pii:dkv014 (epub ahead of print)
31. M.H. Rigatto, T.F. Behle, D.R. Falci, T. Freitas, N.T. Lopes, M. Nunes, L.W. Costa, and A.P. Zavascki Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study J Antimicrob Chemother 70 2015 1552 1557
32. C. Liu, A. Bayer, S.E. Cosgrove, R.S. Daum, S.K. Fridkin, R.J. Gorwitz, S.L. Kaplan, A.W. Karchmer, D.P. Levine, and B.E. Murray Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary Clin Infect Dis 52 2011 285 292
33. M. Falcone, A. Russo, M. Venditti, A. Novelli, and M.P. Pai Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 57 2013 1568 1576
34. A. Di Paolo, M. Polillo, C. Tascini, R. Lewis, F. Menichetti, and R. Danesi Different recommendations for daptomycin dosing over time in patients with severe infections Clin Infect Dis 58 2014 1788 1789
35. M. Falcone, A. Russo, M. Venditti, A. Novelli, and M.P. Pai Reply to Di Paolo et al Clin Infect Dis 58 2014 1789 1790
36. J.K. Ng, L.T. Schulz, W.E. Rose, B.C. Fox, D.R. Andes, K.A. Buhr, and J.T. Fish Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes Antimicrob Agents Chemother 58 2014 88 93
37. I. Mahmood Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics J Pharm Sci 99 2010 2927 2933
38. M.J. Brill, J. Diepstraten, A. van Rongen, S. van Kralingen, J.N. van den Anker, and C.A. Knibbe Impact of obesity on drug metabolism and elimination in adults and children Clin Pharmacokinet 51 2012 277 304
39. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
40. M.P. Pai Estimating the glomerular filtration rate in obese adult patients for drug dosing Adv Chronic Kidney Dis 17 2010 e53 e62
41. A.K. Meagher, A. Forrest, C.R. Rayner, M.C. Birmingham, and J.J. Schentag Population pharmacokinetics of linezolid in patients treated in a compassionate-use program Antimicrob Agents Chemother 47 2003 548 553
42. P. Delanaye, C. Mariat, E. Cavalier, and J.M. Krzesinski Errors induced by indexing glomerular filtration rate for body surface area: reductio ad absurdum Nephrol Dial Transplant 24 2009 3593 3596
43. K. Rowland Yeo, M. Aarabi, M. Jamei, and A. Rostami-Hodjegan Modeling and predicting drug pharmacokinetics in patients with renal impairment Expert Rev Clin Pharmacol 4 2011 261 274
44. A. Chagnac, M. Herman, B. Zingerman, A. Erman, B. Rozen-Zvi, J. Hirsh, and U. Gafter Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption Nephrol Dial Transplant 23 2008 3946 3952
45. A.A. Udy, J.P. Baptista, N.L. Lim, G.M. Joynt, P. Jarrett, L. Wockner, R.J. Boots, and J. Lipman Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations Crit Care Med 42 2014 520 527
46. A.A. Udy, J.A. Roberts, R.J. Boots, D.L. Paterson, and J. Lipman Augmented renal clearance: implications for antibacterial dosing in the critically ill Clin Pharmacokinet 49 2010 1 16
47. A.A. Udy, P. Jarrett, J. Stuart, M. Lassig-Smith, T. Starr, R. Dunlop, S.C. Wallis, J.A. Roberts, and J. Lipman Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds Crit Care 18 2014 657
48. M.P. Pai, and K.A. Rodvold Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity Diagn Microbiol Infect Dis 78 2014 178 187
49. M.P. Pai, P. Cojutti, and F. Pea Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections Clin Pharmacokinet 2015 (epub ahead of print)
50. M.P. Pai, P. Cojutti, and F. Pea Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥ 40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring Clin Pharmacokinet 53 2014 753 762